Therefore, Ocoxin may constitute an effective coadjuvant agent for targeted therapy by directly acting upon metastasis tumor cells and by increasing BRAF inhibitors’ cytotoxicity while impairing tumor microenvironmental support. This evidence concerns the gene BRAF and neoplasm.